Business Wire

SPEECH-PROCESSING-SOLUTI

Share
Philips Speech and Sembly AI Collaborate to Introduce New Cutting-edge Audio Recorders with an AI Meeting Solution

Philips Speech by Speech Processing Solutions, a globally leading innovator in voice technology, has announced that they are taking their cooperation with Sembly AI further by extending their audio recorder range with another three new products. Each new recorder is designed to cover different consumer needs and is equipped with Sembly vouchers for users to experience Sembly's new AI capabilities with a free trial version.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625566533/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Philips VoiceTracer Audio Recorders (Photo: Business Wire)

Excellent audio recording paired with AI technology

"We are delighted to announce that our partnership with Sembly AI opens up new market opportunities by combining the best of both worlds. By providing top-of-the-line audio recorders paired with an AI meeting assistant, we can offer automatic transcriptions, summaries, and action lists for every recording, whether it’s a lecture or a meeting,” explains Dr. Thomas Brauner, CEO of Speech Processing Solutions. “Our innovative solutions enable busy professionals to save time and conduct meetings more efficiently than ever,” he adds.

The new Philips VoiceTracer Audio Recorder DVT4115 and DVT6115, designed for students, boast 3MICs for long-distance recording, ideal for capturing lectures and interviews. Sembly can then transcribe and summarize these recordings. The new Philips VoiceTracer DVT8115, equipped with a 360° microphone, is perfect for recording meeting minutes, with Sembly's easy share function to promptly distribute minutes and action steps to team members. These devices are part of a broader Philips product range, designed to meet diverse recording needs.

Sembly AI offers more than just meeting minutes

The Sembly AI tech startup, founded in 2019, has expanded to offer a wide range of features, including automatic transcription with speaker separation, meeting notes, summaries, and action points. One of the newest innovations is that Sembly AI can now also offer professional AI insights into meetings and conversations, enabling efficient collaboration and streamlined decision-making.

“Our latest AI technology seamlessly integrates with Philips products, adding value whether customers are in the office or on the go. Sembly AI now offers much more than just meeting minutes and we are fully committed to offer new AI services in the coming weeks and months,” explains Gil Makleff, CEO and Co-founder of Sembly AI. “We are proud to collaborate with Philips to enhance the customer experience, empowering users to unlock the full potential of their audio recordings and maximize productivity,” he adds.

These new devices join Philips’ existing portfolio of audio recorders and conference microphones, all compatible with Sembly AI’s software. To discover the entire range of Philips & Sembly products, visit: www.voicetracer.com

About Speech Processing Solutions (SPS):

Speech Processing Solutions (SPS), the global leader in professional dictation solutions, is active in 50+ countries, with over 4 million users and a worldwide network of 1,000+ partners. It develops and markets industry-leading dictation and transcription solutions, automated documentation workflows with speech recognition, as well as award-winning dictation devices, sold under the Philips brand. SPS's mission is to empower every user to be more productive by simplifying their work with smart, voice-based solutions. Headquartered in Vienna, Austria, SPS has regional offices in Australia, Canada, Belgium, France, Germany, the United Kingdom, and the United States.

Follow Us:

LinkedIn: http://www.linkedin.com/company/speech-processing-solutions
YouTube: http://www.youtube.com/philipsdictation
Facebook: https://www.facebook.com/philipsdictation
Instagram: https://www.instagram.com/philips_dictation/

About Sembly AI

Sembly AI is a voice and conversation analytics technology company, focused on bringing the power of natural language processing to professional meeting environments. Sembly’s products can simplify the work life of distributed teams while providing powerful analytics to help teams attend less while getting more done. Sembly AI was founded by CEO Gil Makleff and CPO Artem Koren in 2019. Gil Makleff was CEO of UMT Consulting Group which was acquired by Ernst & Young. Artem Koren was a Senior Manager at Ernst & Young and CTO at Visual Trading Systems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625566533/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release

Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co

Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release

Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM

Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release

Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release

Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface

Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release

Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye